Sonnet BioTherapeutics I... (SONN)
NASDAQ: SONN
· Real-Time Price · USD
7.06
0.58 (8.95%)
At close: Sep 17, 2025, 3:59 PM
7.66
8.50%
Pre-market: Sep 18, 2025, 04:11 AM EDT
8.95% (1D)
| Bid | 6.76 |
| Market Cap | 47.26M |
| Revenue (ttm) | 1M |
| Net Income (ttm) | -13.56M |
| EPS (ttm) | -6.82 |
| PE Ratio (ttm) | -1.04 |
| Forward PE | -0.07 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 7.23 |
| Volume | 2,740,087 |
| Avg. Volume (20D) | 4,387,701 |
| Open | 6.78 |
| Previous Close | 6.48 |
| Day's Range | 6.55 - 7.70 |
| 52-Week Range | 1.08 - 19.30 |
| Beta | 1.22 |
| Ex-Dividend Date | n/a |
About SONN
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol SONN
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for SONN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts2 months ago
+86.46%
Sonnet BioTherapeutics shares are trading higher a...
Unlock content with
Pro Subscription
9 months ago
-5.71%
Sonnet BioTherapeutics shares are trading higher after the company announced the highest dose of its Phase 1 SB101 trial results for SON-1010 have been formally evaluated by the safety review committee, with the maximum tolerated dose set at 1200ng/kg.
